Tenecteplase to treat pulmonary embolism in the emergency department.

Abstract

Tenecteplase, a mutant form of alteplase, possesses pharmacological properties that might favor its use for emergent fibrinolysis of acute pulmonary embolism. Contemporaneous search of the World's literature reveals 14 humans with acute pulmonary embolism treated with tenecteplase. Here, we summarize those cases and report the presentation features, dosing details and outcomes of eight additional patients with acute pulmonary embolism treated with tenecteplase in an academic emergency department. None of our eight patients had a significant hemorrhagic event after tenecteplase, and the outcomes of all eight appear to be acceptable. Taken together, we submit that the present case report and prior case reports are sufficient to comprise a phase I study of the safety and efficacy of tenecteplase to treat acute pulmonary embolism.

• Authors: Jeffrey A Kline, Jackeline Hernandez-Nino, Alan E Jones
• Journal: Journal of thrombosis and thrombolysis (J Thromb Thrombolysis) Vol. 23 Issue 2 Pg. 101-5 (Apr 2007) ISSN: 0929-5305 [Print] Netherlands
• PMID: 17221330 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Fibrinolytic Agents
• Tissue Plasminogen Activator
• Tenecteplase

Topics

• Aged
• Clinical Trials, Phase I as Topic
• Emergency Medical Services (methods)
• Female
• Fibrinolytic Agents (therapeutic use)
• Humans
• Male
• Middle Aged
• Pulmonary Embolism (drug therapy)
• Tenecteplase
• Tissue Plasminogen Activator (therapeutic use)
• Treatment Outcome